Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.

JAK inhibitors and combination therapies show promise for treating severe alopecia areata.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.

SQSTM1 gene issues may increase the risk of alopecia areata.

Patients with fewer past treatments for alopecia areata respond better to baricitinib.

Baricitinib is more effective than methotrexate for severe alopecia areata.

Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.

Baricitinib may effectively treat oral lichen planus.

Alopecia areata causes sudden hair loss, has genetic links, and can be managed but not cured.

New treatments and diagnostic methods for various animal skin conditions showed promising results.

Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.

Higher levels of certain DNAs in blood may indicate hair follicle damage in alopecia areata patients.

Laser therapy might help regrow hair in alopecia totalis better than steroids alone.

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.

Combining epinephrine with a steroid may help regrow hair in severe alopecia areata cases.

Cell death shapes skin stem cell environments, affecting inflammation, repair, and cancer.

Faulty inflammasome activation may lead to autoimmune skin diseases and could be a target for new treatments.

The immune system plays a key role in tissue repair, affecting both healing quality and regenerative ability.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Damage to skin releases dsRNA, which activates TLR3 and helps in skin and hair follicle regeneration.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.